Ajoene (compound of Garlic) / LDH Cancer Research Results

Ajoene, Ajoene (compound of Garlic): Click to Expand ⟱
Features:
Ajoene is a compound found in garlic, specifically in the oil extracted from crushed garlic cloves. It has been studied for its potential anti-cancer properties. Research suggests that ajoene may have several mechanisms by which it can inhibit the growth of cancer cells and induce apoptosis (cell death).

Ajoene — an organosulfur secondary metabolite formed from garlic (Allium sativum) after crushing/processing (an allicin-derived transformation product; typically present as E/Z isomers). It is a thiol-reactive small molecule (vinyl-disulfide sulfoxide motif) studied mainly as a cytotoxic/anti-migratory agent in cancer models and as a topical antifungal. Classification: small-molecule natural product (garlic organosulfur compound). Abbreviation(s): none universally standard; often specified as E-ajoene / Z-ajoene.

Primary mechanisms (ranked):

  1. Protein cysteine modification (S-thiolation / covalent adduct formation on thiol-containing targets), with downstream disruption of signaling and cytoskeletal programs
  2. Pro-oxidant stress in cancer cells (ROS/H2O2 increase, redox-thiol perturbation) that can trigger intrinsic mitochondrial apoptosis
  3. Cell-cycle perturbation (commonly G2/M arrest) and microtubule/cytoskeletal interference (model-dependent; isomer-dependent)
  4. Anti-migration/anti-invasion phenotypes linked to intermediate filament (vimentin) network remodeling (context-dependent)
  5. Secondary: NRF2-driven antioxidant response induction in some non-malignant/epithelial contexts (dose- and context-dependent)

Bioavailability / PK relevance: Systemic human PK is poorly defined; ajoene is typically discussed as an allicin-derived downstream product and allicin itself is not detected in human serum after raw garlic ingestion in classic studies. Practical translation in oncology is therefore most credible for local/topical exposure or for optimized analogues; oral dietary exposure may not reproduce common in-vitro micromolar conditions reliably.

In-vitro vs systemic exposure relevance: Many anticancer studies use ~low–tens of µM in vitro; whether these levels are achievable systemically from diet/supplements is uncertain. Topical delivery can reach higher local concentrations (e.g., skin lesions/fungal infections), and small human topical studies exist.

Clinical evidence status: Predominantly preclinical (cell culture and animal models). Small human topical evidence exists for basal cell carcinoma tumor shrinkage and for fungal skin infections (e.g., tinea pedis; chromoblastomycosis). No robust systemic oncology RCT evidence.

Approximate ajoene content values for different parts of the garlic plant:
Garlic bulbs: 1-5 mg of ajoene per clove
Garlic scapes (green shoots): 0.5-2 mg of ajoene per 100g
Garlic chives (leaves): 0.5-2 mg of ajoene per 100g
Garlic microgreens: 1-5 mg of ajoene per 100g

μM concentrations of ajoene that have been reported to exhibit biological activity:
Antimicrobial activity: 1-10 μM
Antioxidant activity: 1-50 μM
Anti-inflammatory activity: 5-20 μM
Anticancer activity: 10-50 μM
Cardiovascular health: 5-20 μM

Approximate unverified μM concentrations of ajoene that can be achieved with different amounts of garlic or garlic chives:
1 clove of garlic (3g): approximately 1-5 μM of ajoene
1 tablespoon of minced garlic (15g): approximately 5-15 μM of ajoene
1 cup of chopped garlic (100g): approximately 30-60 μM of ajoene
1 tablespoon of chopped garlic chives (15g): approximately 0.5-2 μM of ajoene
1 cup of chopped garlic chives (100g): approximately 5-10 μM of ajoene
1 ounce (28g) of garlic microgreens: approximately 10-30 μM of ajoene
1 cup of garlic microgreens (100g): approximately 30-60 μM of ajoene
1 ounce (28g) of garlic chive microgreens: approximately 5-15 μM of ajoene
1 cup of garlic chive microgreens (100g): approximately 15-30 μM of ajoene

Ajoene — mechanistic axes relevant to oncology translation

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Protein thiol reactivity and covalent cysteine targeting ↑ thiol stress; ↑ protein adducts (model-dependent) ↔ to ↑ adaptive antioxidant response (context-dependent) P/R Upstream “initiator” chemistry that can rewire multiple pathways Consistent with ajoene acting as a thiol-reactive electrophile; downstream effects vary by target set and exposure.
2 ROS and peroxide signaling ↑ ROS/H2O2 (dose-dependent); ↑ oxidative damage (high concentration only) ↔ or ↑ cytoprotective programs (dose-dependent) P Oxidative stress–linked cytotoxicity in susceptible cancer models Classic leukemia data show apoptosis accompanied by ROS and NF-κB activation; magnitude and direction can be model- and dose-dependent.
3 Mitochondria and intrinsic apoptosis ↑ mitochondrial apoptosis; ↑ caspase cascade (model-dependent) ↔ (selectivity reported in some systems) R/G Execution of cell death following redox/thiol perturbation Topical basal cell carcinoma (BCC) work supports mitochondria-dependent apoptosis signaling in vivo/ex vivo.
4 NF-κB signaling ↑ NF-κB activity (model-dependent) P/R Stress-response transcriptional program NF-κB activation can be pro-survival or pro-death depending on context; in some ajoene models it co-occurs with apoptosis rather than preventing it.
5 Cell cycle control and microtubule/cytoskeleton dynamics ↑ G2/M arrest (model-dependent); ↓ proliferation R/G Anti-proliferative cytostasis/cytotoxicity Reported links include microtubule interference and mitotic blockade; may vary by isomer and cellular background.
6 Invasion and migration and vimentin intermediate filaments ↓ invasion/migration (requires vimentin); ↑ vimentin remodeling (context-dependent) G Anti-metastatic phenotype in vitro Non-cytotoxic ajoene concentrations can remodel vimentin networks and suppress invasion/migration in vimentin-positive models.
7 NRF2 antioxidant response (secondary) ↔ to ↑ NRF2 targets (context-dependent) ↑ NRF2-driven cytoprotection (context-dependent) R/G Adaptive redox buffering Ajoene can activate NRF2 and induce glutathione-related enzymes in hepatic/epithelial models; this may oppose pro-oxidant cytotoxicity at lower stress levels.
8 Chemosensitization ↑ apoptosis with chemotherapy (model-dependent) Unknown R/G Potential adjunct effect Reported in leukemia models (including more resistant compartments) but not established clinically for systemic cancer therapy.
9 Clinical Translation Constraint Systemic exposure likely limited/variable from diet; many in-vitro studies use µM levels; isomer mixture and chemical stability complicate reproducibility; best-supported human data are topical (skin/fungal indications). Safety constraint: antiplatelet activity raises bleeding-risk concerns with anticoagulants/antiplatelets. Feasibility boundary Translation most plausible for topical/local delivery or for engineered analogues with validated blood stability and exposure.


LDH, Lactate Dehydrogenase: Click to Expand ⟱
Source:
Type:
LDH is a general term that refers to the enzyme that catalyzes the interconversion of lactate and pyruvate. LDH is a tetrameric enzyme, meaning it is composed of four subunits.
LDH refers to the enzyme as a whole, while LDHA specifically refers to the M subunit. Elevated LDHA levels are often associated with poor prognosis and aggressive tumor behavior, similar to elevated LDH levels.
leakage of LDH is a well-known indicator of cell membrane integrity and cell viability [35]. LDH leakage results from the breakdown of the plasma membrane and alterations in membrane permeability, and is widely used as a cytotoxicity endpoint.

However, it's worth noting that some studies have shown that LDHA is a more specific and sensitive biomarker for cancer than total LDH, as it is more closely associated with the Warburg effect and cancer metabolism.

Dysregulated LDH activity contributes significantly to cancer development, promoting the Warburg effect (Chen et al., 2007), which involves increased glucose uptake and lactate production, even in the presence of oxygen, to meet the energy demands of rapidly proliferating cancer cells (Warburg and Minami, 1923; Dai et al., 2016b). LDHA overexpression favors pyruvate to lactate conversion, leading to tumor microenvironment acidification and aiding cancer progression and metastasis.

Inhibitors:
Flavonoids, a group of polyphenols abundant in fruit, vegetables, and medicinal plants, function as LDH inhibitors.
LDH is used as a clinical biomarker for Synthetic liver function, nutrition


Tier A — Direct LDH Enzyme Inhibitors (Validated Catalytic Inhibition)

Rank Compound Type LDH Target Potency Level Primary Effect Notes
1 NCI-006 Research drug LDHA / LDHB High (in vivo active) Potent glycolysis suppression Modern benchmark LDH inhibitor used in metabolic oncology models.
2 (R)-GNE-140 Research drug LDHA (±LDHB) High (nM range reported) Lactate production ↓ Widely used experimental LDH inhibitor.
3 FX11 Research drug LDHA High (μM range) Metabolic crisis in LDHA-dependent tumors Classic LDHA inhibitor; often increases ROS secondary to metabolic stress.
4 Oxamate Tool compound LDH (pyruvate-competitive) Moderate (mM cellular use) Reduces lactate flux Classical LDH inhibitor; requires high concentrations in cells.
5 Gossypol Natural product derivative LDHA Moderate–High Glycolysis inhibition Also has other targets; safety considerations apply.
6 Galloflavin Natural compound LDH isoforms Moderate Lactate production ↓ One of the better-supported “natural-like” LDH inhibitors.

Tier B — Indirect LDH-Axis Modulators (Glycolysis / Lactate Reduction Without Confirmed Direct Catalytic Inhibition)

Rank Compound Mechanism Type LDH Claim Type Primary Axis Notes / Caution
1 Lonidamine MCT/MPC modulation Lactate axis inhibition Metabolic transport blockade Better classified as lactate/pyruvate transport modulator.
2 Stiripentol Repurposed drug LDH pathway modulation Metabolic axis modulation Emerging oncology interest; primarily neurological drug.
3 Quercetin Flavonoid Reported LDH inhibition (mixed evidence) NF-κB / PI3K modulation Often LDH-release confusion; direct enzymatic proof limited.
4 Ursolic acid Triterpenoid Reported LDH interaction Warburg modulation More credible as metabolic signaling modulator.
5 Fisetin Flavonoid Docking / indirect reports Apoptosis / survival signaling Enzyme inhibition not well validated.
6 Resveratrol Polyphenol Indirect glycolysis suppression AMPK / HIF-1α modulation Reduces lactate via upstream signaling.
7 Curcumin Polyphenol Indirect LDH expression modulation Inflammation + metabolic signaling Bioavailability limits translational strength.
8 Berberine Alkaloid Indirect metabolic modulation AMPK activation Closer to metformin-like metabolic pressure.
9 Honokiol Lignan Indirect glycolysis effects Survival pathway suppression Not validated as catalytic LDH inhibitor.
10 Silibinin Flavonolignan Mixed / indirect reports Inflammation + metabolic axis Often misclassified as LDH inhibitor.
11 Kaempferol Flavonoid Often LDH-release marker confusion Glucose transport / signaling Do not list as direct LDH inhibitor without enzyme data.
12 Oleanolic acid / Limonin / Allicin / Taurine Natural compounds Weak / indirect evidence General metabolic modulation Should not be categorized as true LDH inhibitors.

Tier A = Direct catalytic LDH inhibition (enzyme-level validation).
Tier B = Indirect lactate reduction or glycolytic modulation without strong catalytic inhibition evidence.
Important: LDH release assays (cell damage marker) are not proof of LDH enzymatic inhibition.



Scientific Papers found: Click to Expand⟱
5341- Ajoene,    Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy
- Review, AML, NA
eff↑, AntiThr↑, Bacteria↓, LDH↓, TumCP↓, TumCCA↑, Bcl-2↓, Cyt‑c↑, Casp3↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis

LDH↓, 1,  

Cell Death

Bcl-2↓, 1,   Casp3↑, 1,   Cyt‑c↑, 1,  

Transcription & Epigenetics

AntiThr↑, 1,  

Cell Cycle & Senescence

TumCCA↑, 1,  

Migration

TumCP↓, 1,  

Drug Metabolism & Resistance

eff↑, 1,  

Clinical Biomarkers

LDH↓, 1,  

Infection & Microbiome

Bacteria↓, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: LDH, Lactate Dehydrogenase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:196  Target#:906  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page